Generic Name and Formulations:
Pooled plasma (human) 45–70mg/mL; soln for IV infusion; solvent/detergent treated; frozen; pyrogen-free.
Indications for OCTAPLAS:
Replacement of multiple coagulation factors with acquired deficiencies due to liver disease, undergoing cardiac surgery, or liver transplant. Plasma exchange in thrombotic thrombocytopenic purpura (TTP).
For IV infusion only after thawing. Administer based on ABO-blood group compatibility. Coagulation factors replacement: initially 10–15mL/kg to increase plasma coagulation factor levels approx. 15–25%; if hemostasis is not achieved, use higher doses. Adjust based on response; monitor aPTT, PT, and/or specific coagulation factors. TTP: usually 1–1.5 plasma volumes (40–60mL/kg) to completely replace plasma volume removed during plasmapheresis.
IgA deficiency. Severe Protein S deficiency. Prior hypersensitivity to fresh frozen plasma or plasma-derived products including plasma protein.
Risk of transfusion reactions with ABO blood group mismatches. Risk of hypervolemia with high infusion rates; monitor for signs/symptoms of pulmonary edema or cardiac failure. Hyperfibrinolysis may develop due to low levels of alpha2-antiplasmin; monitor for signs of excessive bleeding in liver transplantation. Monitor for thrombosis. Risk of citrate toxicity; use max infusion rate: 0.020–0.025mmol citrate/kg/min (eg, Octaplas <1mL/kg/min). Contains human plasma; monitor for possible infection transmission (eg, viruses, Creutzfeldt-Jakob disease agent). Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers.
Pooled plasma (human).
Avoid injecting calcium-containing drugs in same IV line.
Pruritus, urticaria, nausea, headache, paresthesia; anaphylactic shock, citrate toxicity, severe hypotension.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC